Managing cancer-related skeletal events with bisphosphonates.
Bone metastases cause considerable morbidity. This article discusses the benefits of bisphosphonates, which are now well established in the treatment of skeletal complications across a wide range of tumour types.
Rule
Simon
S
Department of Haematology, Derriford Hospital, Plymouth PL6 8DH.
D000970:Antineoplastic Agents / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced / Q000517:prevention & control; D001943:Breast Neoplasms / Q000150:complications; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000150:complications; D011471:Prostatic Neoplasms
D000970:Antineoplastic Agents; D004164:Diphosphonates